Correction to “Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension”
Correction to “Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension”. // Comprehensive Physiology. – 2026. – DOI: 10.1002/cph4.70312. – URL: https://onlinelibrary.wiley.com/doi/10.1002/cph4.70312?af=R
(2026). Correction to “Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension”. Comprehensive Physiology. https://doi.org/10.1002/cph4.70312
“Correction to “Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension”.” Comprehensive Physiology, 2026. doi:10.1002/cph4.70312.
@article{article80301,
title = {Correction to “Pharmacokinetic and Pharmacodynamic Consequences of Liver‐Lung Crosstalk: Rethinking Dosing in Hepatopulmonary Syndrome and Portopulmonary Hypertension”},
journal = {Comprehensive Physiology},
year = {2026},
doi = {10.1002/cph4.70312},
url = {https://onlinelibrary.wiley.com/doi/10.1002/cph4.70312?af=R}
}
ABSTRACT Introduction/Aims Pompe disease is a genetic myopathy caused by acid alpha‐glucosidase enzyme deficiency. Treatment response is mainly evaluated using motor scores, for instance the 6‐min walk test (6MWT) or the Motor Function...
ABSTRACT Introduction/Aims Inflammatory neuropathies (IN), such as Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are characterized by peripheral nerve injury driven by immune...